Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 19/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.76 |
| ▸ | PLK3 | Q9H4B4 | 6/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505441 | 0.97 | PLK1 (0.78) | PLK1CYP3A4PLK3CYP2C9 | |
| SCHEMBL14344445 | 0.94 | PLK1 (0.77) | PLK1CYP3A4PLK3CYP2C9 | |
| Hydrochloric Acid SCHEMBL4504409 | 0.93 | PLK1 (0.76) | PLK1CYP3A4PLK3CYP2C9 | |
| SCHEMBL4504509 | 0.93 | PLK1 (0.73) | PLK1CYP3A4PLK3CYP2C9 | |
| SCHEMBL4502142 | 0.92 | PLK1 (0.74) | PLK1CYP3A4PLK3CYP2C9 | |
| SCHEMBL13440263 | 0.90 | PLK1 (0.75) | PLK1CYP3A4PLK3CYP2C9 | |
| SCHEMBL3248696 | 0.90 | PLK1 (0.75) | PLK1CYP3A4PLK3CYP2C9 | |
| SCHEMBL4395208 | 0.89 | PLK1 (0.82) | PLK1CYP3A4PLK3CYP2C9 | |
| SCHEMBL4397176 | 0.89 | PLK1 (0.82) | PLK1CYP3A4PLK3CYP2C9 | |
| SCHEMBL3614869 | 0.88 | PLK1 (0.68) | PLK1CYP3A4PLK3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326029-A1 | NON-CYCLIC SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-12-31 | — | — | US | claimed |
| US-20090326029-A1 | NON-CYCLIC SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-12-31 | — | — | US | disclosed |
| US-20090326029-A1 | NON-CYCLIC SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-12-31 | — | — | US | disclosed |
| US-20090326029-A1 | NON-CYCLIC SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-12-31 | — | — | US | disclosed |
| WO-2007143506-A2 | SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326029-A1 | NON-CYCLIC SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | CYP3A4, CYP2C8, ABCB1 | PLK1 391/4885CYP3A4 1/4885PLK3 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.